Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 1;109(9):2774-2783.
doi: 10.1097/JS9.0000000000000492.

Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis

Shitao Jiang  1 , Yaoge Liu, Han Zheng, Lei Zhang, Haitao Zhao, Xinting Sang, Yiyao Xu, Xin Lu
Affiliations
Review

Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis

Shitao Jiang et al. Int J Surg. .

Abstract

Research has shown that neoadjuvant immunotherapy may provide more significant clinical benefits to cancer patients undergoing surgery than adjuvant therapy. This study examines the development of neoadjuvant immunotherapy research using bibliometric analysis. As of 12 February 2023, articles on neoadjuvant immunotherapy in the Web of Science Core Collection were collected. Co-authorship and keyword co-occurrence analyses and visualizations were performed using VOSviewer, while CiteSpace was used to identify bursting keywords and references. The study analyzed a total of 1222 neoadjuvant immunotherapy publications. The top contributors to this field were the United States, China, and Italy, and the journal with the most publications was Frontiers in Oncology. Francesco Montorsi had the highest H-index. The most common keywords were 'immunotherapy' and 'neoadjuvant therapy'. The study conducted a bibliometric analysis of over 20 years of neoadjuvant immunotherapy research, identifying the countries, institutions, authors, journals, and publications involved in this field. The findings provide a comprehensive overview of neoadjuvant immunotherapy research.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article

Figures

Figure 1
Figure 1
Flow-chart of the study.
Figure 2
Figure 2
Number of publications per year and the cumulative number.
Figure 3
Figure 3
Each country’s contribution to the neoadjuvant immunotherapy.
Figure 4
Figure 4
The top 20 institutions with the most publications in the field of neoadjuvant immunotherapy.
Figure 5
Figure 5
Research hotspots on neoadjuvant immunotherapy (A). keyword co-occurrence network; (B). time-overlapping co-occurrence analysis network of keywords; (C). a list of the 20 most frequently used keywords; (D). the 20 keywords with the strongest citation bursts).
See this image and copyright information in PMC

Comment in

References

    1. Rozeman E, Hoefsmit E, Reijers I, et al. . Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med 2021;27:256–263. - PubMed
    1. Nanda R, Liu MC, Yau C, et al. . Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol 2020;6:676–684. - PMC - PubMed
    1. Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 2020;367:0182. - PMC - PubMed
    1. Hicks D, Wouters P, Waltman L, et al. . Bibliometrics: the Leiden Manifesto for research metrics. Nature 2015;520:429–431. - PubMed
    1. Mukherjee D, Lim WM, Kumar S, et al. . Guidelines for advancing theory and practice through bibliometric research. J Bus Res 2022;148:101–115.

LinkOut - more resources